Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
1. An anti-pSer413 tau antibody or antigen binding fragment thereof comprising:
(A) a heavy chain variable domain comprising:
a vhCDR1 comprising an amino acid sequence of SEQ ID NO:86;
a vhCDR2 comprising an amino acid sequence of SEQ ID NO:115; and
a vhCDR3 comprising an amino acid sequence of SEQ ID NO:88; and
(B) a light chain variable domain comprising a set of vlCDRs selected from the group consisting of:
(i) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:91;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(ii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:92;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(iii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:93;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(vi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:94;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(v) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:95;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(vi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:96;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(vii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:97;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(viii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:98;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(xi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:99;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(x) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:100;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(xi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:101;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83; and
(xii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:102;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83.
2. The anti-pSer413 tau antibody or antigen binding fragment thereof of claim 1 , wherein the ratio of said antibody's binding affinity to a phosphorylated peptide of SEQ ID NO:8 to said antibody's binding affinity to a non-phosphorylated peptide of SEQ ID NO:69 is at least about 40 to 1.
3. A method of treating a tauopathy in a subject, comprising administering to the subject the anti-pSer413 tau antibody or antigen binding fragment thereof of claim 1 .
4. The method of claim 3 , wherein the tauopathy is selected from a group consisting of Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, Pick's disease, argyrophilic grain dementia (argyrophilic grain disease), multiple system tauopathy with presenile dementia (MSTD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), dementia with neurofibrillary tangles, diffuse neurofibrillary tangle with calcification (DNTC), white matter tauopathy with globular glial inclusions (WMT-GGI), frontotemporal lobar degeneration with tau pathology (FTLD-tau), Economo's encephalitis sequela, subacute sclerosing panencephalitis, and boxer's encephalopathy.
5. An anti-pSer413 tau antibody or antigen binding fragment thereof comprising:
(A) a heavy chain variable domain comprising a vhCDR1 comprising an amino acid sequence of SEQ ID NO:86; a vhCDR2 comprising an amino acid sequence of SEQ ID NO:115; a vhCDR3 comprising an amino acid sequence of SEQ ID NO:88; and
(B) a light chain variable domain comprising a vlCDR1 comprising an amino acid sequence of SEQ ID NO:102; a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83.
6. The anti-pSer413 tau antibody or antigen binding fragment thereof of claim 5 , wherein the ratio of said antibody's binding affinity to a phosphorylated peptide of SEQ ID NO:8 to said antibody's binding affinity to a non-phosphorylated peptide of SEQ ID NO:69 is at least about 40 to 1.
7. A method of treating a tauopathy in a subject, comprising administering to the subject the anti-pSer413 tau antibody or antigen binding fragment thereof of claim 5 .
8. The method of claim 7 , wherein the tauopathy is selected from a group consisting of Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, Pick's disease, argyrophilic grain dementia (argyrophilic grain disease), multiple system tauopathy with presenile dementia (MSTD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), dementia with neurofibrillary tangles, diffuse neurofibrillary tangle with calcification (DNTC), white matter tauopathy with globular glial inclusions (WMT-GGI), frontotemporal lobar degeneration with tau pathology (FTLD-tau), Economo's encephalitis sequela, subacute sclerosing panencephalitis, and boxer's encephalopathy.
9. A humanized antibody, or antigen binding fragment thereof, which causes an antigen-antibody reaction with a tau protein or a tau peptide phosphorylated at least on an amino acid residue corresponding to Ser413 of SEQ ID NO: 1, comprising:
(A) a heavy chain variable domain comprising:
a vhCDR1 comprising an amino acid sequence of SEQ ID NO:86;
a vhCDR2 comprising an amino acid sequence of SEQ ID NO:115; and
a vhCDR3 comprising an amino acid sequence of SEQ ID NO:88; and
(B) a light chain variable domain comprising a set of vlCDRs selected from the group consisting of:
(i) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:91;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(ii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:92;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(iii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:93;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(vi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:94;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(v) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:95;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(vi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:96;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(vii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:97;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(viii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:98;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(xi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:99;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(x) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:100;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83;
(xi) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:101;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83; and
(xii) a vlCDR1 comprising an amino acid sequence of SEQ ID NO:102;
a vlCDR2 comprising an amino acid sequence of SEQ ID NO:82; and
a vlCDR3 comprising an amino acid sequence of SEQ ID NO:83.
10. The humanized antibody or antigen binding fragment thereof of claim 9 , wherein the ratio of said antibody's binding affinity to a phosphorylated peptide of SEQ ID NO:8 to said antibody's binding affinity to a non-phosphorylated peptide of SEQ ID NO:69 is at least about 40 to 1.
11. A method of treating a tauopathy in a subject, comprising administering to the subject the humanized antibody or antigen binding fragment thereof of claim 9 .
12. The method of claim 11 , wherein the tauopathy is selected from a group consisting of Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, Pick's disease, argyrophilic grain dementia (argyrophilic grain disease), multiple system tauopathy with presenile dementia (MSTD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), dementia with neurofibrillary tangles, diffuse neurofibrillary tangle with calcification (DNTC), white matter tauopathy with globular glial inclusions (WMT-GGI), frontotemporal lobar degeneration with tau pathology (FTLD-tau), Economo's encephalitis sequela, subacute sclerosing panencephalitis, and boxer's encephalopathy.
13. A humanized antibody or antigen binding fragment thereof, which causes an antigen-antibody reaction with a tau protein or a tau peptide phosphorylated at least on an amino acid residue corresponding to Ser413 of SEQ ID NO: 1, comprising:
(A) a heavy chain variable domain comprising a vhCDR1 comprising an amino acid sequence of 1M (SEQ ID NO: 10); a vhCDR2 comprising an amino acid sequence of 2H1 (SEQ ID NO: 12) or an amino acid sequence differs from sequence 2H1 (SEQ ID NO: 12) in that Ala at position 15 is substituted with Asp; a vhCDR3 comprising an amino acid sequence of 3M (SEQ ID NO: 13); and
(B) a light chain variable domain comprising a vlCDR1 comprising an amino acid sequence of 4L1 (SEQ ID NO: 14) or an amino acid sequence differs from sequence 4L1 (SEQ ID NO: 14) in that Ser at position 5 is substituted with Asn; a vlCDR2 comprising an amino acid sequence of 5M (SEQ ID NO: 16); and a vlCDR3 comprising an amino acid sequence of 6M (SEQ ID NO: 17).
14. The humanized antibody or or antigen binding fragment thereof of claim 13 , comprising:
(A) a vhCDR1 comprising an amino acid sequence of 1M (SEQ ID NO: 10);
a vhCDR2 comprising an amino acid sequence of 2H1 (SEQ ID NO: 12);
a vhCDR3 comprising an amino acid sequence of 3M (SEQ ID NO: 13);
a vlCDR1 comprising an amino acid sequence of 4L1 (SEQ ID NO: 14);
a vlCDR2 comprising an amino acid sequence of 5M (SEQ ID NO: 16); and
a vlCDR3 comprising an amino acid sequence of 6M (SEQ ID NO: 17), or
(B) a vhCDR1 comprising an amino acid sequence of 1M (SEQ ID NO: 10);
a vhCDR2 comprising an amino acid sequence of 2H1 (SEQ ID NO: 12);
a vhCDR3 comprising an amino acid sequence of 3M (SEQ ID NO: 13);
a vlCDR1 comprising an amino acid sequence of 4M (SEQ ID NO: 15);
a vlCDR2 comprising an amino acid sequence of 5M (SEQ ID NO: 16); and
a vlCDR3 comprising an amino acid sequence of 6M (SEQ ID NO: 17), or
(C) a vhCDR1 comprising an amino acid sequence of 1M (SEQ ID NO: 10);
a vhCDR2 comprising an amino acid sequence of 2M (SEQ ID NO: 11);
a vhCDR3 comprising an amino acid sequence of 3M (SEQ ID NO: 13);
a vlCDR1 comprising an amino acid sequence of 4M (SEQ ID NO: 15);
a vlCDR2 comprising an amino acid sequence of 5M (SEQ ID NO: 16); and
a vlCDR3 comprising an amino acid sequence of 6M (SEQ ID NO: 17).
15. The humanized antibody or antigen binding fragment thereof of claim 13 , wherein the ratio of said antibody's binding affinity to a phosphorylated peptide of SEQ ID NO:8 to said antibody's binding affinity to a non-phosphorylated peptide of SEQ ID NO:69 is at least about 40 to 1.
16. A method of treating a tauopathy in a subject, comprising administering to the subject the humanized antibody or antigen binding fragment thereof of claim 13 .
17. The method of claim 16 , wherein the tauopathy is selected from a group consisting of Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, Pick's disease, argyrophilic grain dementia (argyrophilic grain disease), multiple system tauopathy with presenile dementia (MSTD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), dementia with neurofibrillary tangles, diffuse neurofibrillary tangle with calcification (DNTC), white matter tauopathy with globular glial inclusions (WMT-GGI), frontotemporal lobar degeneration with tau pathology (FTLD-tau), Economo's encephalitis sequela, subacute sclerosing panencephalitis, and boxer's encephalopathy.